Wangxian Fu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wangxian Fu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Changyang Gong
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
2 shared publications - Hao Le
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University
2 shared publications - Peng Mi
Department of Radiology, Huaxi MR Research Center (HMRRC) and State Key Laboratory of Biotherapy, West China Hospital, and College of Polymer Science and Engineering, Sichuan University, Chengdu, Sichuan, 610041, China
2 shared publications - Huile Gao
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610064, PR China
1 shared publication - Jiayi Cao1 shared publication
Liping Bai
1 shared publication
Latest Publications
- Open Access
- 1 August 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 62, 263-281
Chronic inflammation-responsive hydrogel restores myeloid-T cell crosstalk to reinvigorate antitumor immunity against metastatic colorectal cancer
Chronic inflammation in intermediate/advanced tumors drives burdensome protumor immune cell communication, thereby weakening immunotherapy. Conventional anti-inflammatory therapies focus on alleviating chronic inflammation whereas ignore dysfunction and scarcity of myeloid and T cells, which hinder their intercellular communication restoration. To address the dilemma, an inflammatory condition-triggered protumor inflammation-immunosurveillance shift hydrogel (TRANS) is developed to initiate adaptive immune responses mediated by intercellular communication. Triggered by inflammatory conditions, TRANS releases celecoxib (CXB) to inhibit the COX-2/PGE2 pathway, thereby reprogramming tumor-associated macrophages and mitigating protumor inflammation. Furthermore, TRANS incorporates FMS-like tyrosine kinase 3 ligands (Flt-3L) and 4-1BB agonists (α-CD137) to respectively recruit type 1 conventional DC (cDC1) and revitalize tumor-infiltrating T cells, to rejuvenate immunosurveillance. TRANS inhibits 87.50% and 88.74% of primary and secondary colorectal tumors, generates antitumor immune memory to resist tumor rechallenge, and significantly reduces lung and liver metastases. Rechallenge model shows TRANS leads to antitumor immune memory formation. Single-cell RNA sequencing is preform to elucidate the mechanism of TRANS, which exhibits that TRANS exerts antitumor effects by optimizing the crosstalk between myeloid cells and T cells via CXCL9/10-CXCR3/DPP4. TRANS further gains better control of colorectal cancer when combined with immune checkpoints inhibitors. This study offers a novel perspective on immunotherapy by rebalancing inflammation-immunity dynamics.
- 1 August 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 62, 263-281
Open AccessChronic inflammation-responsive hydrogel restores myeloid-T cell crosstalk to reinvigorate antitumor immunity against metastatic colorectal cancer
Chronic inflammation in intermediate/advanced tumors drives burdensome protumor immune cell communication, thereby weakening immunotherapy. Conventional anti-inflammatory therapies focus on alleviating chronic inflammation whereas ignore dysfunction and scarcity of myeloid and T cells, which hinder their intercellular communication restoration. To address the dilemma, an inflammatory condition-triggered protumor inflammation-immunosurveillance shift hydrogel (TRANS) is developed to initiate adaptive immune responses mediated by intercellular communication. Triggered by inflammatory conditions, TRANS releases celecoxib (CXB) to inhibit the COX-2/PGE2 pathway, thereby reprogramming tumor-associated macrophages and mitigating protumor inflammation. Furthermore, TRANS incorporates FMS-like tyrosine kinase 3 ligands (Flt-3L) and 4-1BB agonists (α-CD137) to respectively recruit type 1 conventional DC (cDC1) and revitalize tumor-infiltrating T cells, to rejuvenate immunosurveillance. TRANS inhibits 87.50% and 88.74% of primary and secondary colorectal tumors, generates antitumor immune memory to resist tumor rechallenge, and significantly reduces lung and liver metastases. Rechallenge model shows TRANS leads to antitumor immune memory formation. Single-cell RNA sequencing is preform to elucidate the mechanism of TRANS, which exhibits that TRANS exerts antitumor effects by optimizing the crosstalk between myeloid cells and T cells via CXCL9/10-CXCR3/DPP4. TRANS further gains better control of colorectal cancer when combined with immune checkpoints inhibitors. This study offers a novel perspective on immunotherapy by rebalancing inflammation-immunity dynamics.
- Open Access
- 15 July 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (29)
A versatile immunomodulated nanoCRISPR converter augments the susceptibility and visibility of tumors to the immune system
Immune checkpoint blockade (ICB) has potential in alleviating cytotoxic T lymphocyte (CTL) exhaustion. However, resistance that impaired major histocompatibility complex class I (MHC-I) expression on tumors can be developed in many patients after ICB treatment, resulting in insufficient antigen presentation to CTLs. Herein, we rationally design a ver s atile and po w erful i mmunomodula t ed hierar ch ical nanoCRISPR converter (SWITCH) targeting PD-L1 and PCSK9 loci to convert the immune-resistance state of tumors with high PD-L1 and low MHC-I expression for augmenting the susceptibility and visibility of tumors to the immune system. SWITCH possesses enhanced blood circulation and tumor-targeting capacity through PEGylation, acid-triggered pH low insertion peptides (pHLIPs), and interaction of hyaluronan with CD44 receptors. With the assistance of hyaluronidase and preternatural oxidative stress within tumor cells, SWITCH undergoes enzyme-responsive disassembly, charge reversal, rapid lysosomal escape, and efficient disruption of PD-L1 and PCSK9 orderly. This dual-action mechanism simultaneously blocks PD-1/PD-L1 immunosuppression while restoring MHC-I-mediated antigen presentation, resulting in enhanced the susceptibility and visibility of tumors to the immune system. Our results demonstrate SWITCH's remarkable efficacy in suppressing primary, contralateral, and recurrent tumor growth. Taken together, our study provides an encouraging strategy for relieving tumor immune resistance and further potentiating the efficacy of ICB.
- 15 July 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (29)
Open AccessA versatile immunomodulated nanoCRISPR converter augments the susceptibility and visibility of tumors to the immune system
Immune checkpoint blockade (ICB) has potential in alleviating cytotoxic T lymphocyte (CTL) exhaustion. However, resistance that impaired major histocompatibility complex class I (MHC-I) expression on tumors can be developed in many patients after ICB treatment, resulting in insufficient antigen presentation to CTLs. Herein, we rationally design a ver s atile and po w erful i mmunomodula t ed hierar ch ical nanoCRISPR converter (SWITCH) targeting PD-L1 and PCSK9 loci to convert the immune-resistance state of tumors with high PD-L1 and low MHC-I expression for augmenting the susceptibility and visibility of tumors to the immune system. SWITCH possesses enhanced blood circulation and tumor-targeting capacity through PEGylation, acid-triggered pH low insertion peptides (pHLIPs), and interaction of hyaluronan with CD44 receptors. With the assistance of hyaluronidase and preternatural oxidative stress within tumor cells, SWITCH undergoes enzyme-responsive disassembly, charge reversal, rapid lysosomal escape, and efficient disruption of PD-L1 and PCSK9 orderly. This dual-action mechanism simultaneously blocks PD-1/PD-L1 immunosuppression while restoring MHC-I-mediated antigen presentation, resulting in enhanced the susceptibility and visibility of tumors to the immune system. Our results demonstrate SWITCH's remarkable efficacy in suppressing primary, contralateral, and recurrent tumor growth. Taken together, our study provides an encouraging strategy for relieving tumor immune resistance and further potentiating the efficacy of ICB.